EPISODE · May 5, 2026 · 1 MIN
Tactile Medical's Strong Q1: 23% Revenue Growth & Positive EBITDA
from The Daily News Now! Business
Tactile Medical starts 2026 strong with 75.3M revenue, up 23% YoY, driven by 23% growth in lymphedema products and 22% in airway clearance. Gross margins rise to 76.5% and adjusted EBITDA turns positive at 3.7M. The company ends the quarter with 75M in cash, no debt, and completes the Lymphotech acquisition. Investors react positively to the beat on expectations, with full-year revenue guidance raised to 360-368M, implying 9-12% growth. Next-gen AffloVest gets FDA clearance and Lymphotech secures federal funding for advanced garments. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/56d95d7929de4d9e
NOW PLAYING
Tactile Medical's Strong Q1: 23% Revenue Growth & Positive EBITDA
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m